Table 1

Apoptosis-based chemosensitization strategies in clinical trials

Drug/AgentCompanyMechanismStatus
GenasenseGentaBcl-2 antisensePhase II/III
SafingolNCIaPKCb inhibitorPhase I/II
FenretinideNCICeramide generationPhase I/II/III
ELL-12The Liposome Co.MultiplePhase I
UCN-01NCICdkcPhase I/II
FlavopiridolAventisCdkPhase I/II
BMS214662Bristol-Myers SquibbFarnesyl transferasePhase I
SCH66336Schering-PloughFarnesyl transferasePhase II/III
ZarnestraJanssenFarnesyl transferasePhase I/II/III

  • ↵a NCI, National Cancer Institute.

  • ↵b PKC, protein kinase C.

  • ↵c Cdk, cyclin-dependent kinase.